ArticleANZ journal of surgery2025
A Pilot Study of Porcine Acellular Bladder Matrix Filling in the Treatment of Anal Fistulas: A Single-Center Cohort Study.
Article in ANZ journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pilot Study of Porcine Acellular Bladder Matrix Filling in the Treatment of Anal Fistulas: A Single-Center Cohort Study.ANZ journal of surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis study aimed to preliminarily assess the effectiveness of a novel biomaterial, porcine acellular bladder matrix (PABM), in filling fistula tracts. SUMMARY OF BACKGROUND DATA: Anal fistula plugs (AFPs) made from biomaterials are designed to fill fistulas, promote tissue healing, and prevent anal sphincter damage caused by conventional surgeries.
methodsThis single-center cross-sectional study evaluated PABM-AFP treatment for anal fistulas between May 2023 and May 2024. Twenty-eight patients diagnosed with anal fistulas underwent PABM-AFP filling, with follow-up conducted for 6-12 months postoperatively.
resultsThe overall success rate was 89.3%, with an efficacy rate of 90.6% for all treated fistulas. Of the three patients who experienced treatment failure, two recovered after receiving thread-ligating treatment, and the remaining patient who had Crohn's disease experienced partial healing. The mean healing time was 5 weeks, and the average follow-up duration was 7 months. No adverse complications were reported.
conclusionsPABM-AFP is a promising, safe, and effective treatment option for anal fistulas. This study provides valuable preliminary data to support the clinical use of PABM-AFP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.